The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B
Abstract
To assess the prognostic impact of cytogenetics in elderly patients with acute myeloid leukemia (AML) receiving intensive induction and consolidation treatment according to a single protocol specifically designed for patients above age 60, pretreatment samples from 361 patients registered for the AML HD98-B trial of the German-Austrian AML Study Group were analyzed by chromosome banding and fluorescence in situ hybridization, and cytogenetic findings were correlated with outcome. Using a proportional hazards model with backward selection, 3 prognostic subgroups were identified based on the influence of cytogenetic abnormalities on overall survival (OS): low-risk, t(15;17), and inv(16) in 25 of 361 patients (7%); standard-risk, normal karyotype, t(8;21), t(11q23), +8 within a noncomplex karyotype, and +11 within a noncomplex karyotype in 208 of 361 patients (58%); high-risk, all other aberrations in 128 of 361 patients (35%). On multivariate analysis, high-risk cytogenetics (hazard ratio [HR], 2.24) and age above 70 years (HR, 2.34) were independent prognostic factors affecting OS, and stratification according to these parameters demonstrated that a large subgroup of patients (55%), characterized by age 70 or older or high-risk cytogenetics, or both, had very unfavorable treatment results despite intensive chemotherapy. Thus, karyotype and age are major determinants of outcome in elderly patients with AML.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Modeling Survival Data: Extending the Cox Model
Therneau, T. M., & Grambsch, P. M. (2000) · Statistics for Biology and Health · doi:10.1007/978-1-4757-3294-8 · Cited by 8,674
Cited by
Döhner, H., Estey, E. H., Amadori, S., Appelbaum, F. R., Büchner, T., Burnett, A. K., Dombret, H., Fenaux, P., Grimwade, D., Larson, R. A., et al. (2010) · Blood · doi:10.1182/blood-2009-07-235358 · Cited by 3,373
High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia
Löwenberg, B., Ossenkoppele, G. J., van Putten, W., Schouten, H. C., Graux, C., Ferrant, A., Sonneveld, P., Maertens, J., Jongen-Lavrencic, M., von Lilienfeld-Toal, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901409 · Cited by 828
Mutations and prognosis in primary myelofibrosis
Vannucchi, A. M., Lasho, T. L., Guglielmelli, P., Biamonte, F., Pardanani, A., Pereira, A., Finke, C., Score, J., Gangat, N., Mannarelli, C., et al. (2013) · Leukemia · doi:10.1038/leu.2013.119 · Cited by 770
Hurria, A., Levit, L. A., Dale, W., Mohile, S. G., Muss, H. B., Fehrenbacher, L., Magnuson, A., Lichtman, S. M., Bruinooge, S. S., Soto-Perez-de-Celis, E., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.0319 · Cited by 419
Therapy-related myeloid neoplasms: when genetics and environment collide
McNerney, M. E., Godley, L. A., & Le Beau, M. M. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.60 · Cited by 419
Metadata
- Authors
- Fröhling, S., Schlenk, R. F., Kayser, S., Morhardt, M., Benner, A., Döhner, K., Döhner, H., & for the German-Austrian AML Study Group
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2006-11-15
- Volume
- 108
- Issue
- 10
- Pages
- 3280-3288
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2034295250
- Cited by
- 300
- References
- 1
- FWCI
- 11.71
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. https://app.cochat.ai/papers/10.1182/blood-2006-04-014324
- The paper
- Fröhling, S., Schlenk, R. F., Kayser, S., Morhardt, M., Benner, A., Döhner, K., Döhner, H., & for the German-Austrian AML Study Group. (2006). Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. Blood. https://doi.org/10.1182/blood-2006-04-014324
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.